Stockpolly
Search
EQ · NASDAQ · Biotechnology

Equillium (EQ)

Develops EQ504, an investigational AhR modulator for ulcerative colitis and other inflammatory diseases.

$2.20
Pre-market−0.06 (−2.65%)
At close$2.26(+2.49%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue991114124000000
Cost of revenue000000000000
Gross profit991114124000000
12121314139965465
Research & development991011107641233
434332323232
Selling & marketing000000000000
General & administrative434332323232
Other expenses000000000000
Operating income−4−3−30−1−5−9−6−5−4−6−5
01011−1000000
Interest income110000000001
Other non-operating income0−10−1−11000000
Income before tax−3−2−300−5−9−6−4−4−5−5
Income tax expense000000000000
Net income from continuing operations−4−2−300−6−9−6−4−4−5−5
Net income−4−2−300−6−9−6−4−4−5−5
EPS, basic−$0.11−$0.07−$0.08$0.01−$0.00−$0.16−$0.24−$0.16−$0.12−$0.04−$0.06−$0.04
EPS, diluted−$0.11−$0.07−$0.08$0.01−$0.00−$0.16−$0.24−$0.16−$0.12−$0.04−$0.06−$0.04
Weighted average shares, basic3535353535353636369296112
Weighted average shares, diluted3535353735353636369296112
EBITDA−3−2−310−5−9−6−4−4−5−5
Depreciation & amortization000000000000
EBIT−3−2−300−5−9−6−4−4−5−5